Evidence map›Paper›PMID 37507536›Full record

Trial reportActa diabetologica2023

Clinical efficacy and safety of okra (Abelmoschus esculentus (L.) Moench) in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial.

Mahdi Tavakolizadeh, Saeid Peyrovi, Hussein Ghasemi-Moghaddam, Ali Bahadori, Zeynab Mohkami, Mahtab Sotoudeh, Mojtaba Ziaee

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effect ofInternational journal of molecular sciences · 2024
    Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Investigating the Impact ofPlants (Basel, Switzerland) · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Comprehensive Overview of the Effects ofLife (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mahdi TavakolizadehDepartment of Pharmacognosy, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.
Saeid PeyroviMedicinal Plants Research Center, Maragheh University of Medical Sciences, Maragheh, Iran.
Hussein Ghasemi-MoghaddamHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali BahadoriDepartment of Medical Microbiology, Sarab Faculty of Medical Sciences, Sarab, Iran.
Zeynab MohkamiDepartment of Agriculture and Plant Breeding, Agriculture Institute, Research Institute of Zabol, Zabol, Iran.
Mahtab SotoudehDepartment of Pharmacognosy, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.
Mojtaba ZiaeeMedicinal Plants Research Center, Maragheh University of Medical Sciences, Maragheh, Iran. ziaee.m@mrgums.ac.ir.ORCID http://orcid.org/0000-0002-9725-3033
University of Maragheh · IRZanjan University of Medical Sciences · IRTabriz University of Medical Sciences · IRZabol University · IR

Funding

Maragheh University of Medical Sciences 68504
6 · The paper itself

Abstract

aimsThe recent trend toward the use of natural functional and medical supplements has motivated the focus on the search and revival of traditional medicinal plant applications for many years. As a valuable dietary crop, okra fruit (Abelmoschus esculentus (L.) Moench) has been used for thousands of years as a medicinal food. This clinical trial aimed to assess the efficacy and safety of the okra pod capsule as an adjuvant treatment in controlling type 2 diabetes mellitus and provide clinical trial-based evidence about its anti-inflammatory effects.

methodsA total of 100 type II diabetic patients, aged between 40 and 60 years, were randomly assigned into two groups of okra and placebo. The first group was administered 1000 mg of powdered okra fruit three times a day for 3 months, while the other group received a placebo capsule with the same dosage. Both groups continued the standard antidiabetic therapy (consisting of metformin and gliclazide, as well as a nutritional regimen). At the start and three months later, various factors were measured, including FBG, insulin, HbA

resultsAccording to the results, patients who received okra treatment exhibited a significant decrease in FBG, HbA

conclusionsThe present study demonstrated that adjunctive consumption of okra, in type 2 diabetic patients with 1000 mg three times a day for three months, improves lipid profile, glycemic control, and chronic inflammation without any tangible adverse effects. CLINICAL TRIAL REGISTRY: IRCT.Ir (IRCT20120112008712N2). https://www.irct.ir/trial/42042 .

Indexed as

AbelmoschusDiabetes Mellitus, Type 2AdultCholesterolHumansHypoglycemic AgentsMiddle AgedTreatment OutcomeCholesterolHypoglycemic AgentsAbelmoschus esculentusBlood glucoseDiabetesInflammationLipid profilesMedicinal plants

Identifiers

PMID37507536
OpenAlexW4385334714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.